These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 8860739)

  • 1. Urinary 28-kD calbindin-D as a new marker for damage to distal renal tubules caused by cisplatin-based chemotherapy.
    Takashi M; Zhu Y; Miyake K; Kato K
    Urol Int; 1996; 56(3):174-9. PubMed ID: 8860739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significant elevation of urinary 28-kD calbindin-D and N-acetyl-beta-D-glucosaminidase levels in patients undergoing extracorporeal shock wave lithotripsy.
    Takashi M; Hasegawa S; Ohmuta M; Ohshima S; Kato K
    Int Urol Nephrol; 1998; 30(4):407-15. PubMed ID: 9821041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased levels of calbindin-D in serum and urine from patients treated by extracorporeal shock wave lithotripsy.
    Hasegawa S; Kato K; Takashi M; Zhu Y; Obata K; Kinukawa T; Miyake K
    J Urol; 1993 Jun; 149(6):1414-8. PubMed ID: 8501778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamide.
    Hartmann JT; Fels LM; Franzke A; Knop S; Renn M; Maess B; Panagiotou P; Lampe H; Kanz L; Stolte H; Bokemeyer C
    Anticancer Res; 2000; 20(5C):3767-73. PubMed ID: 11268452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary endothelin-1-like immunoreactivity in young male patients with testicular cancer treated by cis-platinum: comparison with other urinary parameters.
    Takeda M; Komeyama T; Tsutsui T; Mizusawa T; Go H; Hatano A; Tanikawa T
    Clin Sci (Lond); 1994 Jun; 86(6):703-7. PubMed ID: 7520380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparison of methods for evaluating the nephrotoxicity of cisplatin].
    Suzumori K; Yasui Y; Suzumori K; Yagami Y; Seki T
    Gan To Kagaku Ryoho; 1988 Aug; 15(8):2251-6. PubMed ID: 3044273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitive enzyme immunoassay for human 28 kDa calbindin-D.
    Zhu YY; Takashi M; Miyake K; Kato K
    Clin Chim Acta; 1991 Sep; 201(3):183-92. PubMed ID: 1756591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early measurement of urinary N-acetyl-β-glucosaminidase helps predict severe hyponatremia associated with cisplatin-containing chemotherapy.
    Arakawa Y; Tamura M; Sakuyama T; Aiba K; Eto S; Yuda M; Tanaka Y; Matsumoto A; Nishikawa K
    J Infect Chemother; 2015 Jul; 21(7):502-6. PubMed ID: 25851853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Studies on serum and urinary alpha 1-microglobulin levels as parameter of the renal function--renal function observed after CDDP administration].
    Ujiie T; Maruta H; Ito N
    Hinyokika Kiyo; 1988 May; 34(5):790-6. PubMed ID: 2459938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of renal calbindin expression during cisplatin-induced kidney injury.
    George B; Szilagyi JT; Joy MS; Aleksunes LM
    J Biochem Mol Toxicol; 2022 Jul; 36(7):e23068. PubMed ID: 35403300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro evaluation of biomarkers for cisplatin-induced nephrotoxicity using HK-2 human kidney epithelial cells.
    Sohn SJ; Kim SY; Kim HS; Chun YJ; Han SY; Kim SH; Moon A
    Toxicol Lett; 2013 Mar; 217(3):235-42. PubMed ID: 23287709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal tubular function in patients treated with high-dose cisplatin.
    Daugaard G; Abildgaard U; Holstein-Rathlou NH; Bruunshuus I; Bucher D; Leyssac PP
    Clin Pharmacol Ther; 1988 Aug; 44(2):164-72. PubMed ID: 2840230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of cisplatin treatment on the urinary excretion of guanidinoacetic acid, creatinine and creatine in patients with urinary tract neoplasm, and on superoxide generation in human neutrophils.
    Yasuda M; Sugahara K; Zhang J; Shuin T; Kodama H
    Physiol Chem Phys Med NMR; 2000; 32(2):119-25. PubMed ID: 11383133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in Urinary Renal Failure Biomarkers in Cancer Patients Initially Treated with Cisplatin.
    Maeda A; Ando H; Ura T; Muro K; Aoki M; Saito K; Kondo E; Takahashi S; Ito Y; Mizuno Y; Fujimura A
    Anticancer Res; 2017 Sep; 37(9):5235-5239. PubMed ID: 28870959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary excretion of glutathione S transferases alpha and pi in patients with proteinuria: reflection of the site of tubular injury.
    Branten AJ; Mulder TP; Peters WH; Assmann KJ; Wetzels JF
    Nephron; 2000 Jun; 85(2):120-6. PubMed ID: 10867517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin-induced urinary endothelin excretion.
    Ohta K; Hirata Y; Shichiri M; Ichioka M; Kubota T; Marumo F
    JAMA; 1991 Mar; 265(11):1391-2. PubMed ID: 1999877
    [No Abstract]   [Full Text] [Related]  

  • 17. Developmental and age-dependent changes of 28-kDa calbindin-D in the central nervous tissue determined with a sensitive immunoassay method.
    Kurobe N; Inaguma Y; Shinohara H; Semba R; Inagaki T; Kato K
    J Neurochem; 1992 Jan; 58(1):128-34. PubMed ID: 1727425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic determinants of cisplatin-induced subclinical kidney injury in oncology patients.
    Ibrahim ME; Chang C; Hu Y; Hogan SL; Mercke N; Gomez M; O'Bryant CL; Bowles DW; George B; Wen X; Buckley B; Aleksunes L; Joy MS
    Eur J Clin Pharmacol; 2019 Jan; 75(1):51-57. PubMed ID: 30220072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profiling of Kidney Injury Biomarkers in Patients Receiving Cisplatin: Time-dependent Changes in the Absence of Clinical Nephrotoxicity.
    George B; Wen X; Mercke N; Gomez M; O'Bryant C; Bowles DW; Hu Y; Hogan SL; Joy MS; Aleksunes LM
    Clin Pharmacol Ther; 2017 Apr; 101(4):510-518. PubMed ID: 28002630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perspectives on using a multiplex human kidney safety biomarker panel to detect cisplatin-induced tubular toxicity in male and female Cynomolgus monkeys.
    Chen Y; Dale Thurman J; Kinter LB; Bialecki R; Eric McDuffie J
    Toxicol Appl Pharmacol; 2017 Dec; 336():66-74. PubMed ID: 29051111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.